Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2009-07-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD002209.pub2PMID 19588333PMCID PMC7097731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Latin Square Design

  2010cited by this paper
• Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study.

  2008cited by this paper
• Substitution treatment of injecting opioid users for prevention of HIV infection.

  2008cited by this paper
• A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification.

  2008cited by this paper
• Exposure to opioid maintenance treatment reduces long-term mortality.

  2008cited by this paper
• A randomized controlled trial of interim methadone maintenance: 10-Month follow-up.

  2007cited by this paper
• A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release.

  2007cited by this paper
• A randomized controlled trial of interim methadone maintenance.

  2006cited by this paper
• Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection.

  2005cited by this paper
• Substitution treatment of injecting opioid users for prevention of HIV infection.

  2004cited by this paper
• The Effectiveness Of Methadone Maintenance Treatment In Controlling Crime An Australian Aggregate-Level Analysis

  2004cited by this paper
• Substitution treatment of injecting opioid users for preventing transmission of HIV infection

  2003cited by this paper
• A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system.

  2003cited by this paper
• Substance-Related Disorders

  2003cited by this paper
• [Opioid-related disorders].

  2003cited by this paper
• Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

  2002cited by this paper
• Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial.

  2000cited by this paper
• Methadone Maintenance Treatment and other Opioid Replacement Therapies

  1997cited by this paper
• Are detoxification programmes effective?

  1996cited by this paper
• Dose-Response Effects of Methadone in the Treatment of Opioid Dependence

  1993cited by this paper
• A treatment outline for approaches to opioid dependence: Quality Assurance Project

  1993cited by this paper
• Key issues in methadone maintenance treatment

  1992cited by this paper
• A randomized trial of an interim methadone maintenance clinic.

  1991cited by this paper
• A controlled trial of methadone maintenance in a population of intravenous drug users in Bangkok: implications for prevention of HIV.

  1991cited by this paper
• Methadone dosage and duration for maintenance treatment.: (468222004-001)

  1983cited by this paper
• "Methadone dosage and duration for maintenance treatment": Critique.: (469682004-001)

  1983cited by this paper
• The Swedish methadone maintenance program: a controlled study.

  1981cited by this paper
• Therapeutic communities vs methadone maintenance. A prospective controlled study of narcotic addiction treatment: design and one-year follow-up.

  1980cited by this paper
• Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong.

  1979cited by this paper
• Methadone treatment of randomly selected criminal addicts.

  1969cited by this paper
• [Drug addiction and drug abuse].

  1969cited by this paper
• Heroin addiction--a metabolic disease.

  1967cited by this paper
• A Medical Treatment for Diacetylmorphine (Heroin) Addiction

  1966cited by this paper
• Surgery of the Gall Bladder and Bile Ducts

  1965cited by this paper
• A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.

  1965cited by this paper
• A Randomized Controlled Trial

  year unknowncited by this paper

• The HEALing Measurement Center: a stepped wedge cluster randomized study protocol to enhance opioid use disorder recovery through measurement based care.

  2026cites this paper
• Between efficacy and ambivalence: Family perceptions of Methadone Maintenance Therapy in Malaysia.

  2026cites this paper
• Iatrogenic physiologic opioid dependence masquerading as recurrent acute pancreatitis flares: case series

  2026cites this paper
• ‘It wasn’t to get high; it was just to get by’: experiences of patients who use fentanyl during methadone treatment and opportunities for improving care in Vermont and New Hampshire

  2026cites this paper
• Exploring the therapeutic potential of psychedelics in treating substance use disorders

  2025cites this paper
• Emerging neuromodulation treatments for opioid and stimulant use disorders

  2025influential citation
• Advancing person-centered care: Protocol for quality measurement and management (QM2) in the New York State system for opioid use disorder treatment

  2025cites this paper
• Injectable buprenorphine during transition out of prison: A pilot partially randomized preference trial protocol

  2025cites this paper
• Factors associated with receipt of second injection of naltrexone for opioid use disorder: Secondary analysis of 5 clinical trials.

  2025cites this paper
• The association between mental disorders and treatment retention among people with opioid use disorder receiving opioid agonist treatment: A systematic review and meta-analysis.

  2025cites this paper
• Health-related quality of life measures as predictors for recurrent hospitalization and mortality among patients in heroin-assisted treatment

  2025cites this paper
• Crosstalk Between Glycinergic and N-Methyl-D-Aspartate Receptor-Mediated Glutamatergic Transmission in Behaviours Associated with Opioid Use Disorder

  2025cites this paper
• Exploring the Gut and Oral Microbiomes in Psychoactive Substance Use: A Scoping Review of Clinical Studies

  2025cites this paper
• Leveraging the 72-Hour Rule Change to Support Transition From Hospital to Opioid Treatment Program

  2025cites this paper
• Case report: Local anesthesia with lidocaine infiltration for extended-release buprenorphine therapy

  2025cites this paper
• Drug delivery strategies for the treatment of relapse behavior in substance use disorder- A systematic review

  2025cites this paper
• Homelessness, type of homelessness, and risk of cause-specific mortality: a systematic review and meta-analysis of 116 studies comprising 2,563,633 homeless people and 129,292,553 population controls

  2025cites this paper
• Examining the association between fentanyl use and perceived adequacy of methadone dose: A retrospective cohort study.

  2025cites this paper
• Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative.

  2025cites this paper
• Initiating Injectable Buprenorphine in People Hospitalized With Infections

  2025cites this paper
• State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset.

  2025cites this paper
• Medications for opioid use disorder shape immune responses during chronic HIV infection

  2025cites this paper
• Effects of the Communities That HEAL intervention on initiation, retention, and linkage to medications for opioid use disorder (MOUD): A cluster randomized wait-list controlled trial.

  2025cites this paper
• Association of Lifetime Psychiatric Comorbidity and Current Substance Use in Methadone-Treated Individuals with Opioid Use Disorders

  2025cites this paper
• Allocative efficiency analysis of strategies to reduce overdose deaths among people with opioid use disorder and history of incarceration in Connecticut

  2025cites this paper
• Seventeen years of experience: a retrospective cohort analysis of methadone maintenance treatment program patterns in Georgia

  2025cites this paper
• Pain Management for Patients With Opioid Use Disorders

  2025cites this paper
• Oral and injectable opioid agonist treatments for people who use street opioids: a systematic literature review and network meta-analysis

  2025cites this paper
• Desirable treatment or a problematic drug scene? – An interview study of patients’ and professionals’ views on the risks and benefits of liberalized opioid agonist treatment

  2025cites this paper
• Real-world longitudinal treatment trajectories following opioid use disorder diagnosis among commercially-insured beneficiaries in the United States.

  2025cites this paper
• Impact of guidance issued during COVID-19 to expand take-home doses of opioid agonist treatment (OAT) in Ireland: protocol for a population-based analysis of prescribing practices and patient outcomes 2018 to 2023

  2025cites this paper
• Exploring Characteristic Parameters to Inform Continued Recovery Among Parenting Women With Opioid Use Disorder in a Residential Facility

  2025cites this paper
• Analyzing the Discursive Framing of Medications for Opioid Use Disorder (MOUDs) in U.S. News Media: A Comparative Study of Benefits, Persuasion Methods, and Temporal Trends.

  2025cites this paper
• Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: A retrospective cohort study.

  2025cites this paper
• Racial Inequality in Receipt of Medications for Opioid Use Disorder in Nationwide Outpatient Settings—A Cross-sectional Study

  2025cites this paper
• Effectiveness of text message reminder and motivational interview on adherence to methadone treatment in Vietnam: a randomized controlled trial.

  2025cites this paper
• Opioid Receptor Signaling Throughout Ontogeny: Shaping Neural and Behavioral Trajectories.

  2025cites this paper
• Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.

  2025cites this paper
• Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data.

  2025cites this paper
• Consensus statement on pain management for pregnant patients with opioid use disorder from the Society for Obstetric Anesthesia and Perinatology, Society for Maternal-Fetal Medicine, and American Society of Regional Anesthesia and Pain Medicine.

  2025cites this paper
• Medicaid Patients With ED Visits For Overdose: Disparities In Initiation Of Medications For Opioid Use Disorder.

  2025cites this paper
• 50 years of harm reduction in Europe: high time for transformation

  2025cites this paper
• Changing trends in drug overdose mortality in Spain, 2001–2022

  2025cites this paper
• Substance Use Disorder and Harm Reduction Curriculum in United States and Canadian Undergraduate Medical Education: An Online Survey

  2025cites this paper
• Medication for opioid use disorder service delivery in carceral facilities: update and summary report

  2025cites this paper
• Approved medications for opioid use disorder : current update

  2025cites this paper
• Reducing stigma and expanding methadone access in the U.S.: the Modernizing Opioid Treatment Access Act and beyond

  2025cites this paper
• “HEAL together”: a randomized, hybrid type 1 effectiveness-implementation trial protocol of a peer-delivered behavioral activation intervention to improve methadone treatment retention

  2025cites this paper
• Opioid agonist therapy for opioid use disorder in primary versus specialty care.

  2025cites this paper
• U.S. states opting out of expanded methadone take-home policies and associated mortality

  2025cites this paper
• Reduction in substance use stigma following a peer-recovery specialist behavioral activation intervention.

  2024cites this paper
• Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder

  2024cites this paper
• DNA methylation patterns in umbilical cord blood from infants of methadone maintained opioid dependent mothers

  2024cites this paper
• Assessing fragility of statistically significant findings from randomized controlled trials assessing pharmacological therapies for opioid use disorders: a systematic review

  2024cites this paper
• A path to recovery for overlooked populations and their unique challenges: integrating rehabilitation in palliative care for patients with substance use disorders

  2024cites this paper
• County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities

  2024cites this paper
• Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorder

  2024cites this paper
• The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder

  2024cites this paper
• Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway

  2024cites this paper
• A combined intervention strategy to increase linkage to and retention in substance use treatment for individuals accessing hospital-based services: study protocol

  2024cites this paper
• Is peer support a tipping point for the opioid use disorder crisis in Appalachia? Research holds the answer

  2024cites this paper
• Relationship between patient activation and utilisation of health care and harm reduction services among people who inject drugs in Baltimore, Maryland.

  2024cites this paper
• Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.

  2024cites this paper
• U.S. Healthcare Workers’ Perspective of Outpatient Provision of Methadone: A Scoping Review

  2024cites this paper
• Opioid-related deaths in Northern Ontario in the early COVID-19 pandemic period

  2024cites this paper
• Community Support for Harm Reduction and Treatment of Opioid Use Disorder

  2024cites this paper
• How I manage severe bacterial infections in people who inject drugs.

  2024cites this paper
• Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia.

  2024cites this paper
• A Harm Reduction Framework for Integrated Treatment of Co-Occurring Opioid Use Disorder and Trauma-Related Disorders

  2024cites this paper
• Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder

  2024cites this paper
• Series of (([1,1'-Biphenyl]-2-yl)methyl)sulfinylalkyl Alicyclic Amines as Novel and High Affinity Atypical Dopamine Transporter Inhibitors with Reduced hERG Activity.

  2024cites this paper
• Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder

  2024cites this paper
• Re: An initial randomized controlled trial of a Combined Medication and Behavioral Activation Treatment (CoMBAT) for people with opioid use disorder.

  2024cites this paper
• Effects Of Medicaid Waivers On Use Of Medications For Opioid Use Disorder And Nonfatal Overdoses In 17 States.

  2024cites this paper
• The association between benzodiazepine co-prescription, opioid agonist treatment and mortality: a systematic review

  2024cites this paper
• Consensus Statement on Pain Management for Pregnant Patients with Opioid-Use Disorder from the Society for Obstetric Anesthesia and Perinatology, Society for Maternal-Fetal Medicine, and American Society of Regional Anesthesia and Pain Medicine

  2024cites this paper
• Evaluating a mobile app’s effects on depression and anxiety in medication-treated opioid use disorder

  2024cites this paper
• Buprenorphine use among non-hospital residential programs.

  2024cites this paper
• Supporting medication-assisted recovery in recovery residences: staff support, managing built environment threats, and building a supportive network

  2024cites this paper
• Medications for opioid use disorder and other evidence-based service offerings in faith-affiliated treatment centers: Implications for implementation partnerships.

  2024cites this paper
• Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

  2024cites this paper
• Road to Recovery: protocol for a mixed-methods prospective cohort study evaluating the impact of a new model of substance use care in a Canadian setting

  2024cites this paper
• Trends in opioid exposures among young children reported to United States poison centers from 2016 to 2023

  2024cites this paper
• Trends in polysubstance use among patients in methadone maintenance treatment in Ireland: Evidence from urine drug testing 2010-2020.

  2024cites this paper
• Exploring the Lived Experiences of Medication for Opioid use Disorder Treatment: A Qualitative Study among a Crowdsourced Convenience Sample

  2024cites this paper
• Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study

  2024cites this paper
• Association between buprenorphine capacity rates and percentages of ethnic/racial minorities at the county level in the United States.

  2024cites this paper
• Experiences and perspectives of sugar-sweetened beverage consumption among Indigenous adults living in Manitoba.

  2024cites this paper
• “SafetyNet”: Evaluation of a Recovery Coach and Paramedic Intervention Following Naloxone Resuscitation From an Opioid Overdose

  2024cites this paper
• Examining the effect of prescription drug monitoring program integration and mandatory use policies on the distribution of methadone and buprenorphine for opioid use disorder, United States, 2009-2021.

  2024cites this paper
• The Clinical Evolutions of Surveillance and Violence During Three Contemporary US Crises: Opioid Overdose, COVID-19, and Racial Reckoning

  2024cites this paper
• The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies

  2024cites this paper
• Expanding access to medication treatment for opioid use disorders: Findings from the Washington State hub and spoke effort.

  2024cites this paper
• Real‐world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada

  2024cites this paper
• Direct effects of heroin and methadone on T cell function.

  2024cites this paper
• Methadone dosing at New York State opioid treatment programs following initial revisions to federal regulations.

  2024cites this paper
• Lost in transition: A protocol for a retrospective, longitudinal cohort study for addressing challenges in opioid treatment for transition-age adults

  2024cites this paper
• A qualitative exploration of harm reduction in practice by street-based peer outreach workers

  2024cites this paper
• The Gut-Brain Axis in Opioid Use Disorder: Exploring the Bidirectional Influence of Opioids and the Gut Microbiome—A Comprehensive Review

  2024cites this paper
• Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)

  2023cites this paper